Fate Therapeutics operates in the immuno-oncology and cellular therapy sector, competing against clinical and commercial innovators such as Allogene Therapeutics, Caribou Biosciences, Editas Medicine, and various other cell-engineering companies developing induced pluripotent stem cell (iPSC) derived CAR-T and natural killer cell therapies.
Silence Therapeutics (NASDAQ: SLN) experiences an average daily trading volume of roughly 825,000 to 866,000 shares, reflecting active market participation by institutional healthcare investors and biotech sector traders across major US exchange sess...
Wall Street and independent equity analysts generally maintain a favorable consensus view on Silence Therapeutics (NASDAQ: SLN), supported by upward earnings estimate revisions and positive clinical data readouts for its proprietary siRNA platform ca...
If referencing Silence Therapeutics (NASDAQ: SLN), Wall Street consensus price targets average approximately $32.60, indicating a projected upside from its trading base.
Investment decisions regarding Silence Therapeutics depend significantly on individual risk profiles, as clinical-stage biotechnology equities carry high volatility and binary clinical trial outcomes.
Precise long-term share price forecasts for clinical-stage biopharmaceutical equities like Silence Therapeutics or Sellas Life Sciences are inherently speculative.
SLN stock represents the American Depositary Shares (ADSs) of Silence Therapeutics PLC (NASDAQ: SLN), a clinical-stage biopharmaceutical company. Each ADS represents three ordinary shares of the company.
The shareholding structure of Silence Therapeutics PLC (NASDAQ: SLN) is heavily institutional, featuring prominent global biotechnology funds, specialist healthcare asset managers, specialized venture funds, and corporate insiders who collectively ho...
SLN can be a compelling asset for growth-oriented investors seeking exposure to cutting-edge RNA interference (RNAi) therapeutics.
Sage Therapeutics operates within the biopharmaceutical and neuroscience sector, competing against major clinical and commercial entities such as Intra-Cellular Therapies, ACADIA Pharmaceuticals, Marinus Pharmaceuticals, Vertex Pharmaceuticals, and B...
Silence Therapeutics PLC American Depository Share (NASDAQ: SLN) maintains a market capitalization of approximately $648 million USD, positioning it as a dynamic small-cap biotechnology enterprise focused on innovative short-interfering ribonucleic a...
Yes, pharmaceutical and biotechnology equities carry a high degree of specific risk due to complex clinical trial phases, strict regulatory approval hurdles by agencies like the FDA, patent expirations, and expensive research overhead.
Silence Therapeutics is actively monitored and covered by a select group of specialized healthcare and biotechnology equity research analysts from prominent global investment banks and financial institutions.
CRISPR Therapeutics (NASDAQ: CRSP) remains a pioneering name in gene editing, backed by landmark regulatory approvals for its sickle cell disease therapies.
Prominent publicly traded gene-editing and CRISPR-focused equities include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM).